Literature DB >> 22454886

Bioavailability of commercial tetracycline products.

D B Barnett1, R N Smith, N D Greenwood, C Hetherington.   

Abstract

1 Thirteen commercial tetracycline products were assessed for bioavailability by in vitro and in vivo tests. Three failed the B.P. disintegration test and three products in a dissolution test released less than 50% of their stated potency by 3 hours. 2 In vivo bioavailability was assessed by serum and urinary data. Six products were tested by serum data over 48 h and their bioavailability profiles varied but their ranking correlated well with in vitro dissolution in water; three were better than the others. In a further study, based on urinary excretion alone, the thirteen products showed considerable variation in bioavailability. One product gave an extremely poor result (6 mg excreted in 24 hours). 3 These findings of generic non-equivalence illustrate the need for adequate standards of bioavailability testing.

Entities:  

Year:  1974        PMID: 22454886      PMCID: PMC1402427          DOI: 10.1111/j.1365-2125.1974.tb00260.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  9 in total

1.  Direct proportionality of urinary excretion rate and serum level of tetracycline in human subjects.

Authors:  T CHULSKI; R H JOHNSON; C A SCHLAGEL; J G WAGNER
Journal:  Nature       Date:  1963-05-04       Impact factor: 49.962

2.  Per cent absorbed time plots derived from blood level and/or urinary excretion data.

Authors:  J G WAGNER; E NELSON
Journal:  J Pharm Sci       Date:  1963-06       Impact factor: 3.534

3.  Distribution and excretion of four tetracycline analogues in normal young men.

Authors:  C M KUNIN; A C DORNBUSH; M FINLAND
Journal:  J Clin Invest       Date:  1959-11       Impact factor: 14.808

4.  Biological availability and in vitro release from oral oxytetracycline and tetracycline preparations.

Authors:  T Bergan; B Oydvin; I Lunde
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1973

5.  Cross-over study of ten tetracycline preparations.

Authors:  J Tuomisto; P Männistö
Journal:  Eur J Clin Pharmacol       Date:  1973-06       Impact factor: 2.953

6.  Generic equivalence and non-equivalence of drugs.

Authors:  R N Smith
Journal:  Lancet       Date:  1972-09-09       Impact factor: 79.321

7.  Serum levels of tetracycline after different administration forms.

Authors:  A E Altmann; H Beeuwkes; P J Brombacher; H J Buytendijk; A H Gijzen; F P Maesen
Journal:  Clin Chim Acta       Date:  1968-05       Impact factor: 3.786

8.  Therapeutic nonequivalence of oxytetracycline capsules.

Authors:  G W Brice; H F Hammer
Journal:  JAMA       Date:  1969-05-19       Impact factor: 56.272

9.  Assessment of the biologic availability of tetracycline products in man.

Authors:  W H Barr; L M Gerbracht; K Letcher; M Plaut; N Strahl
Journal:  Clin Pharmacol Ther       Date:  1972 Jan-Feb       Impact factor: 6.875

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.